Please try another search
For the nine months ended 31 March 2015, Galileo Life Sciences Inc revenues was not reported. Net loss increased from $63K to $1.4M. Higher net loss reflects Consulting fees, related parties increase from $12K to $767K (expense), Legal fees increase from $7K to $86K (expense). Basic Earnings per Share excluding Extraordinary Items totaled to -$0.01.
Period Ending: | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | 0 | |||
Operating Income | -0.2 | -0.93 | -0.29 | -0.2 |
Net Income | -0.19 | -0.93 | -0.29 | -0.18 |
Period Ending: | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 |
---|---|---|---|---|
Total Assets | 0.07 | 0.07 | 0.37 | 0.06 |
Total Liabilities | 0.52 | 0.61 | 0.52 | 0.73 |
Total Equity | -0.45 | -0.54 | -0.15 | -0.67 |
Period Ending: | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -0.12 | -0.11 | -0.03 | -0.29 |
Cash From Investing Activities | -0.07 | -0.07 | -0.07 | -0.02 |
Cash From Financing Activities | 0.19 | 0.17 | 0.1 | 0.32 |
Net Change in Cash | -0 | -0 | -0 | 0 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review